Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 281.84B | 274.18B | 270.40B | 254.11B | 236.81B | 200.42B |
| Gross Profit | 44.59B | 43.30B | 42.18B | 39.13B | 35.38B | 32.29B |
| EBITDA | 15.71B | 15.45B | 15.43B | 15.47B | 11.95B | 12.47B |
| Net Income | 3.07B | 3.57B | 3.85B | 3.50B | 3.08B | 2.78B |
Balance Sheet | ||||||
| Total Assets | 314.32B | 274.28B | 271.48B | 243.93B | 248.56B | 209.37B |
| Cash, Cash Equivalents and Short-Term Investments | 34.54B | 17.48B | 59.27B | 32.52B | 37.32B | 52.34B |
| Total Debt | 90.96B | 73.43B | 62.16B | 63.85B | 67.96B | 55.20B |
| Total Liabilities | 191.56B | 169.90B | 169.20B | 150.24B | 152.69B | 128.69B |
| Stockholders Equity | 54.75B | 51.34B | 50.60B | 49.56B | 50.98B | 46.47B |
Cash Flow | ||||||
| Free Cash Flow | 17.88B | 14.55B | 12.42B | 7.54B | 8.32B | 4.06B |
| Operating Cash Flow | 21.15B | 17.55B | 15.55B | 10.90B | 11.22B | 6.28B |
| Investing Cash Flow | -8.37B | -8.89B | -2.07B | -3.30B | -8.83B | -2.02B |
| Financing Cash Flow | -13.39B | -16.84B | -4.07B | -9.00B | 5.31B | -3.60B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
China Resources Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$44.48B | 9.43 | 7.86% | 7.07% | 1.13% | -13.53% | |
74 Outperform | HK$32.72B | 11.94 | 14.91% | 4.01% | -0.45% | 9.00% | |
73 Outperform | HK$29.04B | 13.78 | 12.65% | 3.18% | 10.56% | -13.58% | |
68 Neutral | €28.96B | 9.52 | 5.90% | 2.95% | ― | ― | |
65 Neutral | HK$33.10B | 18.50 | 10.01% | 2.25% | 11.78% | 19.06% | |
65 Neutral | $78.48B | 17.15 | 6.75% | 1.57% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Group Ltd. announced that its subsidiary, CR Pharmaceutical Commercial, has received approval from the National Association of Financial Market Institutional Investors to issue medium term notes in China. The registration allows for the issuance of up to RMB3 billion in notes over two years, with proceeds intended for repaying interest-bearing debt, potentially impacting the company’s financial stability and market positioning.
China Resources Pharmaceutical Group Ltd. has announced proposed amendments to its Articles of Association, aiming to align with the latest legal and regulatory requirements concerning treasury shares and shareholder communication. These changes are subject to shareholder approval at an upcoming extraordinary general meeting, reflecting the company’s commitment to compliance and operational transparency.
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB1.1 billion. The proceeds will be utilized for various operational expenses, including debt repayment, working capital replenishment, and investments in scientific and technological innovations, which may strengthen the company’s financial position and support its growth initiatives.
China Resources Pharmaceutical Group Ltd. has announced the formation of a new fund with a proposed size of RMB500 million, aimed at investing in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology. The company’s subsidiaries, CR Pharm (Shantou), CR Double-Crane, and CR Pharmaceutical Investment, will collectively contribute RMB123 million, representing 24.6% of the total capital commitment. The fund will not be considered a subsidiary of the company, and Shenzhen CR Capital will manage it. This move is a connected transaction under the Hong Kong Listing Rules, due to the involvement of Hanwei Huayou Shantou, a connected person of the company.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a revenue increase to RMB 1.47 billion compared to the previous year, but net profit decreased to RMB 343 million. Additionally, there was a significant reduction in cash and cash equivalents, highlighting potential liquidity challenges. The financials, prepared under PRC accounting standards, have not been audited and may be subject to adjustments, urging caution among shareholders and investors.
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from RMB 3.24 billion. The financials highlight a net decrease in cash and cash equivalents and a significant rise in total assets and liabilities, indicating potential adjustments during auditing, and advising caution for shareholders and investors.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company saw a slight decrease in revenue compared to the previous year, but net profit increased, indicating improved operational efficiency. The financials show a positive cash flow and an increase in total assets, suggesting a stable financial position. However, the figures have not been audited and may be subject to adjustments, prompting caution among investors.
KPC Pharmaceuticals, Inc., partially owned by China Resources Pharmaceutical Group Ltd., reported a decrease in revenue and net profit for the nine months ending September 30, 2025, compared to the previous year. The financial results indicate a net decrease in cash and cash equivalents, highlighting potential challenges in liquidity. The announcement advises caution for shareholders and potential investors due to the unaudited nature of the financials, which may require adjustments.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the nine months ending September 30, 2025. The company saw an increase in revenue and net profit compared to the previous year, with revenue reaching RMB 4.77 billion and net profit at RMB 1.28 billion. Despite a decrease in total assets, the company experienced a positive net increase in cash and cash equivalents, indicating improved liquidity. Stakeholders are advised to exercise caution as the financials are unaudited and may require adjustments.
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a slight decline in revenue and net profit compared to the previous year, with revenue at RMB 8.28 billion and net profit at RMB 1.39 billion. Despite a decrease in cash and cash equivalents, the company saw an increase in total assets and owner’s equity, indicating a stable financial position. Shareholders and investors are advised to exercise caution as the financials are unaudited and may require adjustments.
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive cash flow change and a stable asset base, suggesting a solid financial position for Tasly, which could impact China Resources Pharmaceutical Group’s overall market standing and investor confidence.
China Resources Pharmaceutical Group Ltd. announced the successful issuance of the first tranche of its 2025 corporate bonds in China, amounting to RMB1.1 billion with a 1.82% annual coupon rate. The proceeds will be used for various operational and developmental purposes, including debt repayment and investment in scientific and technological innovations, potentially enhancing the company’s operational capabilities and market position.
China Resources Pharmaceutical Group Ltd. announced a change in its executive leadership, with Mdm. Deng Rong resigning as an executive director and member of the executive committee, while continuing her role as CFO. Concurrently, Mr. Liu Changan has been appointed as an executive director and member of the executive committee, bringing his experience from previous roles within the company and other organizations. These changes are expected to maintain the company’s strategic direction and stability, ensuring continued focus on its growth and operational goals.
China Resources Pharmaceutical Group Ltd. has announced the list of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the leadership structure, which is crucial for stakeholders to understand the company’s governance and strategic direction.